scholarly journals Jinlong capsule inhibits migration and invasion in human glioblastoma cells via the modulation of mTOR/S6 signaling pathway

2019 ◽  
Vol Volume 13 ◽  
pp. 1023-1032 ◽  
Author(s):  
Jingren Shi ◽  
Wenli Zhang ◽  
Lu He ◽  
Fanhong Kong ◽  
Meichen Pan ◽  
...  
2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Araceli Gutiérrez-Rodríguez ◽  
Valeria Hansberg-Pastor ◽  
Ignacio Camacho-Arroyo

Progesterone-induced blocking factor (PIBF) is a progesterone (P4) regulated protein expressed in different types of high proliferative cells including astrocytomas, the most frequent and aggressive brain tumors. It has been shown that PIBF increases the number of human astrocytoma cells. In this work, we evaluated PIBF regulation by P4 and the effects of PIBF on proliferation, migration, and invasion of U87 and U251 cells, both derived from human glioblastomas. PIBF mRNA expression was upregulated by P4 (10 nM) from 12 to 24 h. Glioblastoma cells expressed two PIBF isoforms, 90 and 57 kDa. The content of the shorter isoform was increased by P4 at 24 h, while progesterone receptor antagonist RU486 (10 μM) blocked this effect. PIBF (100 ng/mL) increased the number of U87 cells on days 4 and 5 of treatment and induced cell proliferation on day 4. Wound-healing assays showed that PIBF increased the migration of U87 (12–48 h) and U251 (24 and 48 h) cells. Transwell invasion assays showed that PIBF augmented the number of invasive cells in both cell lines at 24 h. These data suggest that PIBF promotes proliferation, migration, and invasion of human glioblastoma cells.


ACS Omega ◽  
2021 ◽  
Vol 6 (6) ◽  
pp. 4289-4299
Author(s):  
Jinbiao Xiong ◽  
Gaochao Guo ◽  
Lianmei Guo ◽  
Zengguang Wang ◽  
Zhijuan Chen ◽  
...  

2019 ◽  
Vol 1717 ◽  
pp. 117-126 ◽  
Author(s):  
Xiang Ding ◽  
Gang Deng ◽  
Junhui Liu ◽  
Baohui Liu ◽  
Fan'en Yuan ◽  
...  

2009 ◽  
Vol 109 (1) ◽  
pp. 203-213 ◽  
Author(s):  
Hua Guo ◽  
Feng Gu ◽  
Wenliang Li ◽  
Baogang Zhang ◽  
Ruifang Niu ◽  
...  

2021 ◽  
Vol 14 ◽  
Author(s):  
Yiyun Liu ◽  
Yangsheng Chen ◽  
Ruihong Zhu ◽  
Li Xu ◽  
Heidi Qunhui Xie ◽  
...  

Glioblastoma is the most frequent and aggressive primary astrocytoma in adults. The high migration ability of the tumor cells is an important reason for the high recurrence rate and poor prognosis of glioblastoma. Recently, emerging evidence has shown that the migration ability of glioblastoma cells was inhibited upon the activation of aryl hydrocarbon receptor (AhR), suggesting potential anti-tumor effects of AhR agonists. Rutaecarpine is a natural compound with potential tumor therapeutic effects which can possibly bind to AhR. However, its effect on the migration of glioblastoma is unclear. Therefore, we aim to explore the effects of rutaecarpine on the migration of human glioblastoma cells U87 and the involvement of the AhR signaling pathway. The results showed that: (i) compared with other structural related alkaloids, like evodiamine and dehydroevodiamine, rutaecarpine was a more potent AhR activator, and has a stronger inhibitory effect on the glioblastoma cell migration; (ii) rutaecarpine decreased the migration ability of U87 cells in an AhR-dependent manner; (iii) AhR mediated the expression of a tumor suppressor interleukin 24 (IL24) induced by rutaecarpine, and AhR-IL24 axis was involved in the anti-migratory effects of rutaecarpine on the glioblastoma. Besides IL24, other candidates AhR downstream genes both associated with cancer and migration were proposed to participate in the migration regulation of rutaecarpine by RNA-Seq and bioinformatic analysis. These data indicate that rutaecarpine is a naturally-derived AhR agonist that could inhibit the migration of U87 human glioblastoma cells mostly via the AhR-IL24 axis.


2014 ◽  
Vol 53 (2) ◽  
pp. 262-270 ◽  
Author(s):  
Qingming Meng ◽  
Tongle Zhi ◽  
Yuewen Chao ◽  
Er Nie ◽  
Xuebin Xu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document